Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

Zacks Investment Research • Aug 19, 2026

LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

Zacks Investment Research • Aug 17, 2026

Why Liquidia Stock Was Diving This Week

The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.

The Motley Fool • Aug 14, 2026

LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path

Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.

Zacks Investment Research • Aug 13, 2026

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Zacks Investment Research • Aug 13, 2026

Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow

YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus.

Seeking Alpha • Aug 13, 2026

Liquidia Q2 Earnings Call Highlights

Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.

MarketBeat • Aug 12, 2026

Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript

Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

Liquidia Corporation Reports Second Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an increase in cash and cash equivalents of $61.4 million compared to the first quarter of 2026 Progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil MORRISVILLE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026.

GlobeNewsWire • Aug 12, 2026

Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates

Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to a loss of $0.49 per share a year ago.

Zacks Investment Research • Aug 12, 2026